These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 33389405)

  • 21. Prognostic value of tumor-infiltrating lymphocytes in patients with triple-negative breast cancer: a systematic review and meta-analysis.
    Gao G; Wang Z; Qu X; Zhang Z
    BMC Cancer; 2020 Mar; 20(1):179. PubMed ID: 32131780
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Triple-negative breast cancer has worse overall survival and cause-specific survival than non-triple-negative breast cancer.
    Li X; Yang J; Peng L; Sahin AA; Huo L; Ward KC; O'Regan R; Torres MA; Meisel JL
    Breast Cancer Res Treat; 2017 Jan; 161(2):279-287. PubMed ID: 27888421
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Patterns of Recurrence and Predictors of Survival in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy, Surgery, and Radiation.
    Keilty D; Nezafat Namini S; Swain M; Maganti M; Cil TD; McCready DR; Cescon DW; Amir E; Fleming R; Mulligan AM; Fyles A; Croke JM; Liu FF; Levin W; Koch CA; Han K
    Int J Radiat Oncol Biol Phys; 2020 Nov; 108(3):676-685. PubMed ID: 32407932
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inflammatory TNBC Breast Cancer: Demography and Clinical Outcome in a Large Cohort of Patients With TNBC.
    Biswas T; Efird JT; Prasad S; James SE; Walker PR; Zagar TM
    Clin Breast Cancer; 2016 Jun; 16(3):212-6. PubMed ID: 26988771
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of Body Mass Index on Survival in Breast Cancer Patients According to Subtype, Metabolic Syndrome, and Treatment.
    Cho WK; Choi DH; Park W; Cha H; Nam SJ; Kim SW; Lee JE; Yu J; Im YH; Ahn JS; Park YH; Kim JY; Ahn S
    Clin Breast Cancer; 2018 Oct; 18(5):e1141-e1147. PubMed ID: 29753627
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Role of Body Mass Index in Triple Negative Breast Cancer.
    Cakar B; Muslu U; Erdogan AP; Ozisik M; Ozisik H; Tunakan Dalgic C; Durusoy R; Karaca B; Sezgin C; Karabulut B; Uslu R
    Oncol Res Treat; 2015; 38(10):518-22. PubMed ID: 26452262
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Copy number alteration is an independent prognostic biomarker in triple-negative breast cancer patients.
    Nagahashi M; Ling Y; Toshikawa C; Hayashida T; Kitagawa Y; Futamura M; Kuwayama T; Nakamura S; Yamauchi H; Yamauchi T; Kaneko K; Kanbayashi C; Sato N; Tsuchida J; Moro K; Nakajima M; Shimada Y; Ichikawa H; Lyle S; Miyoshi Y; Takabe K; Okuda S; Wakai T
    Breast Cancer; 2023 Jul; 30(4):584-595. PubMed ID: 36930419
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical characteristics, risk factors, and outcomes in Chilean triple negative breast cancer patients: a real-world study.
    Acevedo F; Walbaum B; Medina L; Merino T; Camus M; Puschel K; Ramírez K; Manzor M; Veglia P; Martinez R; Guerra C; Navarro M; Bauerle C; Dominguez F; Sánchez C
    Breast Cancer Res Treat; 2023 Jan; 197(2):449-459. PubMed ID: 36414796
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical activity of adjuvant cytokine-induced killer cell immunotherapy in patients with post-mastectomy triple-negative breast cancer.
    Pan K; Guan XX; Li YQ; Zhao JJ; Li JJ; Qiu HJ; Weng DS; Wang QJ; Liu Q; Huang LX; He J; Chen SP; Ke ML; Zeng YX; Xia JC
    Clin Cancer Res; 2014 Jun; 20(11):3003-11. PubMed ID: 24668644
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The expressions of NEDD9 and E-cadherin correlate with metastasis and poor prognosis in triple-negative breast cancer patients.
    Li P; Sun T; Yuan Q; Pan G; Zhang J; Sun D
    Onco Targets Ther; 2016; 9():5751-5759. PubMed ID: 27703373
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Outcomes of non-metastatic triple negative breast cancers: Real-world data from a large Indian cohort.
    Bajpai J; Kashyap L; Vallathol DH; Das A; Singh M; Pathak R; Rath S; Sekar A; Mohanta S; Reddy A; Joshi S; Nandhana R; Ravind R; Wadasadawala T; Nair N; Ghosh J; Parmar V; Gulia S; Desai S; Shet T; Thakur M; Patil A; Sarin R; Gupta S; Badwe R
    Breast; 2022 Jun; 63():77-84. PubMed ID: 35334242
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Validation of the DNA Damage Immune Response Signature in Patients With Triple-Negative Breast Cancer From the SWOG 9313c Trial.
    Sharma P; Barlow WE; Godwin AK; Parkes EE; Knight LA; Walker SM; Kennedy RD; Harkin DP; Logan GE; Steele CJ; Lambe SM; Badve S; Gökmen-Polar Y; Pathak HB; Isakova K; Linden HM; Porter P; Pusztai L; Thompson AM; Tripathy D; Hortobagyi GN; Hayes DF
    J Clin Oncol; 2019 Dec; 37(36):3484-3492. PubMed ID: 31657982
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Increased CD4 and CD8-positive T cell infiltrate signifies good prognosis in a subset of triple-negative breast cancer.
    Matsumoto H; Thike AA; Li H; Yeong J; Koo SL; Dent RA; Tan PH; Iqbal J
    Breast Cancer Res Treat; 2016 Apr; 156(2):237-47. PubMed ID: 26960711
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Safety of breast-conserving treatment for triple-negative breast cancer].
    Wang L; Ouyang T; Wang T; Xie Y; Fan Z; Fan T; Li J
    Zhonghua Wai Ke Za Zhi; 2015 Dec; 53(12):947-52. PubMed ID: 26850668
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Metaplastic Carcinoma of the Breast Is More Aggressive Than Triple-negative Breast Cancer: A Study From a Single Institution and Review of Literature.
    El Zein D; Hughes M; Kumar S; Peng X; Oyasiji T; Jabbour H; Khoury T
    Clin Breast Cancer; 2017 Aug; 17(5):382-391. PubMed ID: 28529029
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic significance of proline, glutamic acid, leucine rich protein 1 (PELP1) in triple-negative breast cancer: a retrospective study on 129 cases.
    Zhang Y; Dai J; McNamara KM; Bai B; Shi M; Chan MS; Liu M; Sasano H; Wang X; Li X; Liu L; Ma Y; Cao S; Xing Y; Zhao B; Song Y; Wang L
    BMC Cancer; 2015 Oct; 15():699. PubMed ID: 26472563
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of Adjuvant Treatments for T1 N0 M0 Triple-Negative Breast Cancer.
    Zhai Z; Zheng Y; Yao J; Liu Y; Ruan J; Deng Y; Zhou L; Zhao P; Yang S; Hu J; We B; Wu Y; Zhang D; Kang H; Dai Z
    JAMA Netw Open; 2020 Nov; 3(11):e2021881. PubMed ID: 33211105
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Triple Negative Breast Cancer: 10-Year Survival Update of The Applied Treatment Strategy in Kuwait.
    Fayaz S; Demian GA; El-Sherify M; Eissa H; Aziz M; Abuzallouf S
    Gulf J Oncolog; 2019 Jan; 1(29):53-59. PubMed ID: 30957764
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of body mass index on clinical outcomes in triple-negative breast cancer.
    Ademuyiwa FO; Groman A; O'Connor T; Ambrosone C; Watroba N; Edge SB
    Cancer; 2011 Sep; 117(18):4132-40. PubMed ID: 21387276
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term survival analysis of addition of carboplatin to neoadjuvant chemotherapy in HER2-negative breast cancer.
    Iwase M; Ando M; Aogi K; Aruga T; Inoue K; Shimomura A; Tokunaga E; Masuda N; Yamauchi H; Yamashita T; Iwata H
    Breast Cancer Res Treat; 2020 Apr; 180(3):687-694. PubMed ID: 32140811
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.